Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
The disgraced film producer was diagnosed with leukaemia in November. Now his lawyer has confirmed that the 72-year-old was ...
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...
Genmab A/S (GMAB) announced new results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell ...
No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin’s Lymphoma, Cemsidomide Monoth Much of the East Coast was in for a polar reprieve. But that warm-up comes with a price: ...
Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...
An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12 ...
Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...
An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...
Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...
Whatever form it takes, successful treatment reverses the changes in brain circuitry that make substance use hard to control. Yet many factors other than biology must be addressed for treatment to ...